ClinicalTrials.gg
CompletedNCT01546623Updated Jul 21, 2015Results posted

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

A Phase 3 interventional study of TAP-144-SR(6M) and TAP-144-SR(3M) in Prostate Cancer, sponsored by Takeda. Completed at 16 sites in Japan. Open to male participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-07-21.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
18th of 69
160 · median 77
Started
2012
the only one that year
Phase 3
26 of 70
3 open now
Registered
31st of 70
by date
Lead sponsor
3 of 70
Takeda

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 18th largest by enrollment of the 69 interventional ones that give a count, is the only one that started in 2012, is one of 26 in phase 3, and was the 31st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 20 Years to 85 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) against TAP-144-SR(3M) in prostate cancer patients previously treated with hormonal therapy.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant has histopathologically confirmed prostate cancer in Japanese.
  2. The participant has prostate cancer in the clinical stages of T1b-T4, N-any and M-any by TNM classification on clinical diagnosis at the time of diagnosis.
  3. The participant has performance status of grades 0, 1, or 2 at screening.
  4. The participant with PSA level which has not increased 25 % or greater and 2 ng/mL or more from the nadir at the measurement points 4 weeks or longer apart within the screening period of 12 weeks.
  5. Patients who receive the marketed product for 3 months (LEUPLIN SR FOR INJECTION KIT 11.25) at screening
  6. Patients who have received the marketed products, TAP-144-SR (1M) and TAP-144-SR (3M), for 24-96 weeks in total at the scheduled starting date of the study drug, but not including administration period treated as therapy for prostatectomy and/or radiation therapy
  7. Patients who have continued the nonsteroidal antiandrogen for longer than 12 weeks at the scheduled starting date of the study drug, if a nonsteroidal antiandrogen is concomitantly administered
  8. The participant with a serum testosterone level at screening \< 100ng/dL
  9. The participant meets the following criteria of renal, bone-marrow and hepatic functions on the laboratory test results at screening:

(1) Renal function: serum creatinine level\< 1.5 times the (ULN) (2) Bone-marrow function: white blood count ≥ 3,500/ mm3, count ≥ 100,000/L, ≥ 10.0g/dL (3) Hepatic function: (GOT), ALT(GPT), ALP and total ≤ 2.5 times the ULN 10. The participant's is at least 24 months at .

Exclusion criteria

Exclusion Criteria:

  1. The participant has active multiple primary cancers, (synchronous multiple primary cancer or metachronous multiple primary cancer with the disease-free survival ≤ 5 years)
  2. The participant has received surgical castration.
  3. The participant has ever received LHRH agonists other than commercially available 1-month or 3-month depot of leuprolide acetate.
  4. The participant has ever received LHRH antagonists.
  5. Patients who have previously received estrogen preparations or for prostate cancer
  6. Patients who have previously received chemotherapy for prostate cancer
  7. Patients who are receiving or received the marketed product for 3 months (LEUPLIN SR FOR INJECTION KIT 11.25) or the marketed products for 1 month (LEUPLIN FOR INJECTION 3.75 and KIT 3.75) as an therapy after prostatectomy and/or radiotherapy
  8. Patients who are receiving or received the marketed product for 3 months (LEUPLIN SR FOR INJECTION KIT 11.25) for intermittent androgen deprivation therapy
  9. Patients who received the following drugs within 24 weeks (168 days) after starting the study drug: Steroidal antiandrogens, type II 5α-reductase inhibitors
  10. The participant received any of the following within 16 weeks (112 days) prior to study enrollment:

(1) Radiotherapy. As for I-125 brachytherapy, within 35 weeks (245 days) prior to study enrollment.

(2) Prostatectomy (3) Experimental therapy including high-intensity focused ultrasound therapy (HIFU), immunotherapy, and gene therapy 11. Patients who received the following drugs within 4 weeks (28 days) before starting the study drug: Testosterones, ketoconazole(except for external preparations), spironolactone, corticosteroids (excluding their inhalants and external preparations), and Chinese medicines and dietary supplements containing saw palmetto 12. Patients whose interval exceeded 460 msec on the 12-lead at screening 13. The participant has a history of to synthetic LHRH, LHRH derivative or any component of the study drug.

  1. The participant has central nervous system which requires treatment or which is symptomatic.
  1. The participant already has a history or has a complication or may have renal disorder caused by spinal cord compression or ureteric obstruction.
  1. The participant has a history of serious drug allergic reaction/hypersensitivity 17. The participant has a history of, or has been diagnosed with thromboembolism including myocardial infarction, cerebral infarction, venous thrombosis, and pulmonary embolism, or cardiac failure
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    TAP-144-SR(6M)

    TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.

    Drug: TAP-144-SR(6M)

  • Active comparator
    TAP-144-SR(3M)

    TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.

    Drug: TAP-144-SR(3M)

Interventions

06

What researchers measure

Primary outcomes

  1. The Rate of Suppression of Serum Testosterone to Castrate Level

    Comparison of the proportion of patients maintained at castration level (≤100 ng/dL)

    Time frame: From the start of study drug administration through Week 48

Secondary outcomes

  1. Time Course of Changes in Serum Testosterone

    Time frame: From baseline to Week 48

  2. Time Course of Changes in Serum Luteinizing Hormone (LH)

    Time frame: From baseline to Week 48

  3. Time Course of Changes in Serum Follicle-stimulating Hormone (FSH)

    Time frame: From baseline to Week 48

  4. Time Course of Change Rate in Serum PSA (FAS)

    Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by prostate-specific antigen \[PSA\])

    Time frame: From baseline to Week 48

  5. The Maximum Rate of Change in PSA Suppression (FAS)

    Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)

    Time frame: From baseline to Week 48

  6. Percentage of Participants With Progression by PSA (FAS)

    Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)

    Time frame: From baseline to Week 48

  7. Soft Tissue Response

    Assessment in accordance with the "criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition. Soft tissue response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: At week 48

  8. Bone Lesion Response

    Partially revised assessment based on the "criteria for therapeutic effect" from the General Rule for Clinical and Pathological Studies on Prostate Canter, 4th edition. Response is measured using bone scintigraphy. Increase in new (2 or more) bone lesion is considered as progression

    Time frame: At Week 48

  9. Serum Unchanged TAP-144 Level

    Time frame: From baseline to Week 48

  10. 12-lead ECG

    Time frame: At 1 hour, week 24, and week 48 after administration

07

Results

Posted Jul 21, 2015

Participant flow

Participants took part in the study at 23 investigative sites in Japan from 11 April 2012 to 04 April 2014.

Participant flow — Overall Study
MilestoneTAP-144-SR(6M)TAP-144-SR(3M)
Started8280
Received study drug8179
Completed7674
Not completed66
Withdrew: Adverse event23
Withdrew: Major protocol deviation11
Withdrew: High prostate specific antigen21
Withdrew: Did not receive study drug11

Outcome measures

PrimaryThe Rate of Suppression of Serum Testosterone to Castrate Level

Comparison of the proportion of patients maintained at castration level (≤100 ng/dL)

Time frame:
From the start of study drug administration through Week 48
Reported as:
Number · Participants
The Rate of Suppression of Serum Testosterone to Castrate Level
ParticipantsTAP-144-SR(6M)TAP-144-SR(3M)
Number of participants maintained8178
Number of participants who did not maintain01
SecondaryTime Course of Changes in Serum Testosterone
Time frame:
From baseline to Week 48
Reported as:
Median · ng/dL
Time Course of Changes in Serum Testosterone
ng/dLTAP-144-SR(6M)TAP-144-SR(3M)
Baseline8.0 (0 to 33)7.0 (0 to 388)
Week 16.0 (0 to 33)7.0 (0 to 267)
Week 27.0 (0 to 37)6.0 (0 to 55)
Week 47.0 (0 to 35)8.0 (0 to 33)
Week 87.5 (0 to 53)8.0 (0 to 33)
Week 127.0 (0 to 41)8.0 (0 to 36)
Week 167.0 (0 to 45)7.5 (0 to 34)
Week 208.0 (0 to 43)6.0 (0 to 40)
Week 247.0 (0 to 37)6.0 (0 to 33)
Week 256.0 (0 to 30)5.5 (0 to 30)
Week 265.0 (0 to 35)4.0 (0 to 32)
Week 288.0 (0 to 36)6.0 (0 to 36)
Week 329.0 (0 to 41)8.0 (0 to 30)
Week 368.0 (0 to 34)7.0 (0 to 40)
Week 408.0 (0 to 39)8.0 (0 to 37)
Week 447.0 (0 to 37)8.0 (0 to 33)
Week 489.0 (0 to 42)6.0 (0 to 34)
SecondaryTime Course of Changes in Serum Luteinizing Hormone (LH)
Time frame:
From baseline to Week 48
Reported as:
Median · mIU/mL
Time Course of Changes in Serum Luteinizing Hormone (LH)
mIU/mLTAP-144-SR(6M)TAP-144-SR(3M)
Baseline0.000 (0.00 to 1.44)0.000 (0.00 to 12.25)
Week 10.160 (0.00 to 1.03)0.220 (0.00 to 7.57)
Week 20.180 (0.00 to 0.68)0.150 (0.00 to 2.91)
Week 40.120 (0.00 to 0.37)0.110 (0.00 to 0.65)
Week 80.000 (0.00 to 0.33)0.000 (0.00 to 0.67)
Week 120.000 (0.00 to 0.35)0.110 (0.00 to 1.56)
Week 160.000 (0.00 to 0.38)0.055 (0.00 to 0.87)
Week 200.000 (0.00 to 0.36)0.110 (0.00 to 0.58)
Week 240.000 (0.00 to 1.38)0.000 (0.00 to 0.63)
Week 250.150 (0.00 to 0.67)0.185 (0.00 to 0.54)
Week 260.170 (0.00 to 0.84)0.130 (0.00 to 0.48)
Week 280.110 (0.00 to 0.35)0.000 (0.00 to 0.59)
Week 320.000 (0.00 to 0.26)0.000 (0.00 to 0.66)
Week 360.000 (0.00 to 0.24)0.000 (0.00 to 0.76)
Week 400.000 (0.00 to 0.31)0.000 (0.00 to 0.49)
Week 440.000 (0.00 to 0.32)0.000 (0.00 to 0.66)
Week 480.000 (0.00 to 0.42)0.000 (0.00 to 0.84)
SecondaryTime Course of Changes in Serum Follicle-stimulating Hormone (FSH)
Time frame:
From baseline to Week 48
Reported as:
Median · mIU/mL
Time Course of Changes in Serum Follicle-stimulating Hormone (FSH)
mIU/mLTAP-144-SR(6M)TAP-144-SR(3M)
Baseline5.120 (1.93 to 13.31)4.780 (2.02 to 18.52)
Week 15.430 (1.87 to 15.52)4.810 (1.77 to 17.62)
Week 24.890 (1.99 to 13.12)4.710 (1.81 to 16.40)
Week 44.625 (1.72 to 14.11)4.950 (1.49 to 16.19)
Week 85.225 (1.90 to 13.75)5.240 (1.79 to 17.23)
Week 125.340 (2.24 to 14.04)5.110 (1.86 to 15.97)
Week 165.300 (2.07 to 13.87)5.370 (1.81 to 15.65)
Week 205.030 (1.65 to 12.21)5.260 (1.91 to 15.01)
Week 244.990 (1.97 to 13.45)5.150 (2.12 to 16.47)
Week 255.210 (2.16 to 12.92)4.970 (1.84 to 17.02)
Week 265.010 (2.34 to 13.14)5.020 (1.96 to 14.69)
Week 285.060 (2.31 to 13.38)5.070 (2.05 to 13.63)
Week 325.210 (2.32 to 13.20)5.030 (2.08 to 12.54)
Week 365.585 (2.01 to 13.00)4.970 (2.09 to 14.08)
Week 405.100 (1.80 to 14.85)4.910 (2.05 to 13.20)
Week 445.150 (1.69 to 12.90)4.990 (2.17 to 14.14)
Week 485.110 (1.44 to 11.69)4.820 (2.18 to 14.46)
SecondaryTime Course of Change Rate in Serum PSA (FAS)

Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by prostate-specific antigen \[PSA\])

Time frame:
From baseline to Week 48
Reported as:
Median · percent change
Time Course of Change Rate in Serum PSA (FAS)
percent changeTAP-144-SR(6M)TAP-144-SR(3M)
Week 4-7.930 (-100.00 to 181.82)-10.000 (-100.00 to 122.95)
Week 8-14.255 (-100.00 to 190.06)-15.880 (-100.00 to 184.85)
Week 12-20.810 (-100.00 to 360.84)-21.130 (-100.00 to 754.55)
Week 16-19.720 (-100.00 to 634.69)-20.650 (-100.00 to 1866.67)
Week 20-44.740 (-100.00 to 932.65)-39.970 (-100.00 to 3718.18)
Week 24-49.270 (-100.00 to 2002.04)-31.110 (-100.00 to 9900.00)
Week 28-56.705 (-100.00 to 2920.41)-45.875 (-100.00 to 15354.55)
Week 32-57.690 (-100.00 to 7389.80)-40.745 (-100.00 to 21051.52)
Week 36-60.710 (-100.00 to 9675.51)-50.520 (-100.00 to 23506.06)
Week 40-80.610 (-100.00 to 5348.98)-58.520 (-100.00 to 21627.27)
Week44-74.105 (-100.00 to 6859.18)-54.585 (-100.00 to 24506.06)
Week 48-72.900 (-100.00 to 6818.37)-59.400 (-100.00 to 22839.39)
SecondaryThe Maximum Rate of Change in PSA Suppression (FAS)

Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)

Time frame:
From baseline to Week 48
Reported as:
Median · percent change
The Maximum Rate of Change in PSA Suppression (FAS)
percent changeTAP-144-SR(6M)TAP-144-SR(3M)
The Maximum Rate of Change in PSA Suppression (FAS)-86.225 (-100.00 to 108.73)-67.030 (-100.00 to 75.76)
SecondaryPercentage of Participants With Progression by PSA (FAS)

Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)

Time frame:
From baseline to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Progression by PSA (FAS)
percentage of participantsTAP-144-SR(6M)TAP-144-SR(3M)
Presence of disesase progression: Yes7.592.5
Presence of disesase progression: No6.593.5
SecondarySoft Tissue Response

Assessment in accordance with the "criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition. Soft tissue response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
At week 48
Reported as:
Number · Percentage of participants
Soft Tissue Response
Percentage of participantsTAP-144-SR(6M)TAP-144-SR(3M)
Complete response0.00.0
Partial Response0.00.0
Stable Disease13.911.8
Progressive Disease0.02.6
Not Evaluable86.185.5
SecondaryBone Lesion Response

Partially revised assessment based on the "criteria for therapeutic effect" from the General Rule for Clinical and Pathological Studies on Prostate Canter, 4th edition. Response is measured using bone scintigraphy. Increase in new (2 or more) bone lesion is considered as progression

Time frame:
At Week 48
Reported as:
Number · Percentage of participants
Bone Lesion Response
Percentage of participantsTAP-144-SR(6M)TAP-144-SR(3M)
Presence of disesase progression: New lesions ≥ 21.31.3
Presence of disesase progression: New lesions < 198.798.7
SecondarySerum Unchanged TAP-144 Level
Time frame:
From baseline to Week 48
Reported as:
Mean · ng/dL
Serum Unchanged TAP-144 Level
ng/dLTAP-144-SR(6M)TAP-144-SR(3M)
Baseline0.07113 ± 0.0438080.06188 ± 0.035339
Week 10.1304 ± 0.163880.1869 ± 0.077198
Week 20.3085 ± 0.305230.1335 ± 0.083060
Week 40.8845 ± 0.526950.1132 ± 0.12110
Week 80.1792 ± 0.103540.08374 ± 0.041078
Week 120.1256 ± 0.0688600.08039 ± 0.056305
Week 160.1024 ± 0.0939510.1220 ± 0.067137
Week 200.06957 ± 0.0536820.08450 ± 0.039532
Week 240.05167 ± 0.0432210.07437 ± 0.045186
Week 250.1353 ± 0.298090.1978 ± 0.083286
Week 260.4318 ± 0.631010.1418 ± 0.087312
Week 280.7622 ± 0.424830.1067 ± 0.054505
Week 320.1524 ± 0.0983080.08236 ± 0.046180
Week 360.1091 ± 0.0575820.08407 ± 0.075147
Week 400.09118 ± 0.0657710.1086 ± 0.051455
Week 440.06958 ± 0.0556240.08639 ± 0.051923
Week 480.04596 ± 0.0300060.07945 ± 0.066980
Secondary12-lead ECG
Time frame:
At 1 hour, week 24, and week 48 after administration
Reported as:
Mean · msec
12-lead ECG
msecTAP-144-SR(6M)TAP-144-SR(3M)
QTcF interval measurement at Basline429.0 ± 15.75436.2 ± 15.63
QTcF interval measurement at 1 hour422.2 ± 20.80432.2 ± 21.93
QTcF interval measurement at Week 24425.0 ± 20.01433.4 ± 18.91
QTcF interval measurement at Week 48428.1 ± 16.42431.7 ± 16.05

Adverse events

Collected over From the first dose of study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open-label study drug (up to 56 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAP-144-SR(6M)—10/81 (12.3%)74/81 (91.4%)
TAP-144-SR(3M)—8/79 (10.1%)71/79 (89.9%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventTAP-144-SR(6M)TAP-144-SR(3M)
Inguinal herniaGastrointestinal disorders1/811/79
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/811/79
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/811/79
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/811/79
Diabetes mellitusMetabolism and nutrition disorders0/811/79
Peripheral arterial occlusive diseaseVascular disorders0/811/79
Calculus bladderRenal and urinary disorders0/811/79
Appendicitis perforatedInfections and infestations0/811/79
Disuse syndromeGeneral disorders0/811/79
CataractEye disorders0/811/79
Most frequent other events
Showing 10 of 17
Most frequent other events
EventTAP-144-SR(6M)TAP-144-SR(3M)
NasopharyngitisInfections and infestations18/8125/79
Injection site indurationGeneral disorders14/8111/79
Injection site erythemaGeneral disorders12/816/79
Back painMusculoskeletal and connective tissue disorders2/818/79
Blood creatine phosphokinase increasedInvestigations5/817/79
Dental cariesGastrointestinal disorders6/811/79
Injection site painGeneral disorders6/815/79
FallInjury, poisoning and procedural complications6/813/79
ContusionInjury, poisoning and procedural complications6/811/79
ConstipationGastrointestinal disorders3/815/79

Baseline characteristics

The population included all participants who were randomized to treatment.

Age, Continuous
Age, Continuous(Years)TAP-144-SR(6M)TAP-144-SR(3M)Total
Mean73.3 ± 6.3272.6 ± 6.4973.0 ± 6.39
Sex: Female, Male
Sex: Female, Male(Participants)TAP-144-SR(6M)TAP-144-SR(3M)Total
Female000
Male8280162
Weight
Weight(kg)TAP-144-SR(6M)TAP-144-SR(3M)Total
Mean64.03 ± 8.68965.83 ± 8.09864.92 ± 8.424
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)TAP-144-SR(6M)TAP-144-SR(3M)Total
Mean23.61 ± 2.73124.32 ± 2.76923.96 ± 2.764
Gleason Score
Gleason Score(Participants)TAP-144-SR(6M)TAP-144-SR(3M)Total
20 ± 0.00 ± 0.00
30 ± 0.00 ± 0.00
40 ± 0.00 ± 0.00
52 ± 2.42 ± 2.54
68 ± 9.87 ± 8.815
735 ± 42.729 ± 36.364
814 ± 17.121 ± 26.335
920 ± 24.421 ± 26.341
103 ± 3.703
Tumor-node-metastasis (TNM) classification at diagnosis: T
Tumor-node-metastasis (TNM) classification at diagnosis: T(Participants)TAP-144-SR(6M)TAP-144-SR(3M)Total
T00 ± 0.00 ± 0.00
T117 ± 20.716 ± 20.333
T232 ± 39.024 ± 30.456
T329 ± 35.433 ± 41.862
T44 ± 4.96 ± 7.610
TX0 ± 0.00 ± 0.00
Unknown0 ± 00 ± 0.00
TNM classification at diagnosis: N
TNM classification at diagnosis: N(Participant)TAP-144-SR(6M)TAP-144-SR(3M)Total
N06962131
N1131730
NX000
Unknown000
TNM classification at diagnosis: M
TNM classification at diagnosis: M(participants)TAP-144-SR(6M)TAP-144-SR(3M)Total
M06362125
M1191736
Unknown000

3 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • Nagoya-shi, Aichi, Japan
  • Chiba-shi, Chiba, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Maebashi-shi, Gunma, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Kanazawa-shi, Ishikawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Sendai-shi, Miyagi, Japan
  • Nigata-shi, Nigata, Japan
  • Osaka-shi, Osaka, Japan
  • Suita-shi, Osaka, Japan
  • Ageo-shi, Saitama, Japan
  • Kita-adachi-gun, Saitama, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Itabashi-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2012
First posted
Mar 7, 2012
Start
Mar 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Jul 21, 2015
Last update
Jul 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01546623
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 7, 2012
Start date
Mar 2012
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Jul 21, 2015
Last update
Jul 21, 2015

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion